Free Trial
NASDAQ:AKBA

Akebia Therapeutics (AKBA) Stock Price, News & Analysis

Akebia Therapeutics logo
$3.88 -0.09 (-2.27%)
Closing price 04:00 PM Eastern
Extended Trading
$3.88 0.00 (0.00%)
As of 06:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Akebia Therapeutics Stock (NASDAQ:AKBA)

Key Stats

Today's Range
$3.81
$3.98
50-Day Range
$2.32
$3.99
52-Week Range
$1.07
$4.08
Volume
2.87 million shs
Average Volume
3.16 million shs
Market Capitalization
$1.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.75
Consensus Rating
Buy

Company Overview

Akebia Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

AKBA MarketRank™: 

Akebia Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 262nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Akebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Akebia Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Akebia Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.30) to ($0.14) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Akebia Therapeutics is -18.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Akebia Therapeutics is -18.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Akebia Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.01% of the float of Akebia Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Akebia Therapeutics has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Akebia Therapeutics has recently increased by 37.84%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Akebia Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Akebia Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.01% of the float of Akebia Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Akebia Therapeutics has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Akebia Therapeutics has recently increased by 37.84%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Akebia Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Akebia Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    Only 6 people have searched for AKBA on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Akebia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $258,841.00 in company stock.

  • Percentage Held by Insiders

    Only 3.00% of the stock of Akebia Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 33.92% of the stock of Akebia Therapeutics is held by institutions.

  • Read more about Akebia Therapeutics' insider trading history.
Receive AKBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKBA Stock News Headlines

Akebia Therapeutics (NASDAQ:AKBA) Hits New 1-Year High - What's Next?
Your blueprint for crypto wealth
Mark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…
Akebia Therapeutics, Inc. (AKBA) - Yahoo Finance
See More Headlines

AKBA Stock Analysis - Frequently Asked Questions

Akebia Therapeutics' stock was trading at $1.90 on January 1st, 2025. Since then, AKBA stock has increased by 103.9% and is now trading at $3.8750.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) released its quarterly earnings results on Thursday, May, 8th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.06. The biopharmaceutical company earned $57.34 million during the quarter, compared to analyst estimates of $44.88 million.
Read the conference call transcript
.

Top institutional investors of Akebia Therapeutics include Wealth Enhancement Advisory Services LLC (0.01%). Insiders that own company stock include John P Butler, Steven Keith Burke, Michel Dahan, Nicole R Hadas, David A Spellman, Erik Ostrowski, Nicholas Grund and Richard C Malabre.
View institutional ownership trends
.

Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akebia Therapeutics investors own include Novavax (NVAX), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC) and Exxon Mobil (XOM).

Company Calendar

Last Earnings
5/08/2025
Today
7/15/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AKBA
CIK
1517022
Employees
430
Year Founded
N/A

Price Target and Rating

High Price Target
$8.00
Low Price Target
$6.00
Potential Upside/Downside
+71.8%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$69.41 million
Net Margins
-24.51%
Pretax Margin
-24.51%
Return on Equity
N/A
Return on Assets
-18.92%

Debt

Debt-to-Equity Ratio
1.89
Current Ratio
2.23
Quick Ratio
2.02

Sales & Book Value

Annual Sales
$160.18 million
Price / Sales
6.44
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.23) per share
Price / Book
-17.08

Miscellaneous

Outstanding Shares
262,640,000
Free Float
254,757,000
Market Cap
$1.03 billion
Optionable
Optionable
Beta
0.88

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:AKBA) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners